DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
GSK3174998
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
GSK3174998
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GW813893
2
Small molecule
Investigational
Unknown
Unknown
Venous Thromboembolism
Unknown
GW813893
×
Maximum Phase:
2
First Approval:
None
UNII:
1Y3JD5PEMS
Molecule Type:
Small molecule
Molecular Formula:
C17H22ClN3O5S2
Molecular Weight:
447.97
AlogP:
1.14
PSA:
96.02
HBD:
1.0
HBA:
#RotB:
6.0
Source:
FX-005
2
Small molecule
Investigational
Unknown
Unknown
Osteoarthritis, Knee
MAP kinase p38 alpha inhibitor
FX-005
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MIVAVOTINIB
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MIVAVOTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
8QR88H79VX
Molecule Type:
Small molecule
Molecular Formula:
C17H21FN6O
Molecular Weight:
344.39
AlogP:
1.55
PSA:
97.86
HBD:
3.0
HBA:
#RotB:
3.0
Source:
RSLV-132
2
Unknown
Investigational
Unknown
Unknown
Lupus Erythematosus, Systemic; Severe Acute Respiratory Syndrome; Sjogren's Syndrome
RNA hydrolytic enzyme
RSLV-132
×
Maximum Phase:
2
First Approval:
None
UNII:
6RQ92PNH8Z
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ARTEFENOMEL
2
Small molecule
Investigational
Unknown
Unknown
Malaria; Malaria, Falciparum; Malaria, Vivax; Schistosomiasis haematobia
Unknown
ARTEFENOMEL
×
Maximum Phase:
2
First Approval:
None
UNII:
RIK029813G
Molecule Type:
Small molecule
Molecular Formula:
C28H39NO5
Molecular Weight:
469.62
AlogP:
4.88
PSA:
49.39
HBD:
0.0
HBA:
#RotB:
5.0
Source:
QUARFLOXIN
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma; Carcinoid Tumor; Leukemia, Lymphocytic, Chronic, B-Cell
Unknown
QUARFLOXIN
×
Maximum Phase:
2
First Approval:
None
UNII:
8M31J5031Q
Molecule Type:
Small molecule
Molecular Formula:
C35H33FN6O3
Molecular Weight:
604.69
AlogP:
5.39
PSA:
92.59
HBD:
1.0
HBA:
#RotB:
6.0
Source:
ADC3680
2
Small molecule
Investigational
Unknown
Unknown
Asthma
G protein-coupled receptor 44 antagonist
ADC3680
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SPEBRUTINIB BESYLATE
2
Small molecule
Investigational
Unknown
Unknown
Leukemia; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid
Tyrosine-protein kinase BTK inhibitor
SPEBRUTINIB BESYLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
RC3ET192UJ
Molecule Type:
Small molecule
Molecular Formula:
C28H28FN5O6S
Molecular Weight:
581.63
AlogP:
4.25
PSA:
97.4
HBD:
3.0
HBA:
#RotB:
10.0
Source:
MANGO JUICE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
MANGO JUICE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GOLVATINIB
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Squamous Cell; Neoplasms; Stomach Neoplasms
Hepatocyte growth factor receptor inhibitor
GOLVATINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
516Z3YP58E
Molecule Type:
Small molecule
Molecular Formula:
C33H37F2N7O4
Molecular Weight:
633.7
AlogP:
4.75
PSA:
119.14
HBD:
3.0
HBA:
#RotB:
8.0
Source:
ICE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
ICE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
APR-246
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
APR-246
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
QAX-576
2
Antibody
Investigational
Unknown
Unknown
Asthma; Crohn Disease; Eosinophilic Esophagitis; Idiopathic Pulmonary Fibrosis; Keloid; Pulmonary Fibrosis; Rhinitis, Allergic, Seasonal; Scleroderma, Systemic
Interleukin-13 inhibitor
QAX-576
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EVORPACEPT
2
Protein
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Carcinoma, Squamous Cell
Unknown
EVORPACEPT
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DIHOMO-GAMMA-LINOLENIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Dermatitis, Atopic
Unknown
DIHOMO-GAMMA-LINOLENIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
FC398RK06S
Molecule Type:
Small molecule
Molecular Formula:
C20H34O2
Molecular Weight:
306.49
AlogP:
6.44
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
15.0
Source:
JBPOS-0101
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
JBPOS-0101
×
Maximum Phase:
2
First Approval:
None
UNII:
D7NM51C3GU
Molecule Type:
Small molecule
Molecular Formula:
C10H12ClNO3
Molecular Weight:
229.66
AlogP:
1.86
PSA:
72.55
HBD:
2.0
HBA:
#RotB:
3.0
Source:
PROFLAVINE
2
Small molecule
Investigational
Unknown
Unknown
Genital Neoplasms, Female; Barrett Esophagus; Carcinoma, Squamous Cell; Uterine Neoplasms
DNA disrupting agent
PROFLAVINE
×
Maximum Phase:
2
First Approval:
None
UNII:
CY3RNB3K4T
Molecule Type:
Small molecule
Molecular Formula:
C13H11N3
Molecular Weight:
209.25
AlogP:
2.55
PSA:
64.93
HBD:
2.0
HBA:
#RotB:
0.0
Source:
ACYLINE
2
Protein
Investigational
Unknown
Unknown
Hypogonadism
Gonadotropin-releasing hormone receptor antagonist
ACYLINE
×
Maximum Phase:
2
First Approval:
None
UNII:
S3439D3B35
Molecule Type:
Protein
Molecular Formula:
C80H102ClN15O14
Molecular Weight:
1533.24
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
GSK-3117391
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Unknown
GSK-3117391
×
Maximum Phase:
2
First Approval:
None
UNII:
CKA3P0O1VI
Molecule Type:
Small molecule
Molecular Formula:
C22H33N3O4
Molecular Weight:
403.52
AlogP:
3.04
PSA:
100.55
HBD:
3.0
HBA:
#RotB:
9.0
Source:
BLZ945
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Amyotrophic Lateral Sclerosis
Unknown
BLZ945
×
Maximum Phase:
2
First Approval:
None
UNII:
7W3V82OQ0P
Molecule Type:
Small molecule
Molecular Formula:
C20H22N4O3S
Molecular Weight:
398.49
AlogP:
3.56
PSA:
96.37
HBD:
3.0
HBA:
#RotB:
5.0
Source:
VB-201
2
Small molecule
Investigational
Unknown
Unknown
Colitis, Ulcerative; Psoriasis; Severe Acute Respiratory Syndrome
Monocyte differentiation antigen CD14 inhibitor
VB-201
×
Maximum Phase:
2
First Approval:
None
UNII:
SJ5A8151JO
Molecule Type:
Small molecule
Molecular Formula:
C29H60NO8P
Molecular Weight:
581.77
AlogP:
6.33
PSA:
114.35
HBD:
1.0
HBA:
#RotB:
30.0
Source:
TADOCIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Integrin alpha-IIb/beta-3 antagonist
TADOCIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
R34T642CGV
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DEMCIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms
Delta-like protein 4 inhibitor
DEMCIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
SF168W7FW0
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RUSALATIDE ACETATE
2
Protein
Investigational
Unknown
Unknown
Radius Fractures
Unknown
RUSALATIDE ACETATE
×
Maximum Phase:
2
First Approval:
None
UNII:
9J556O9JPD
Molecule Type:
Protein
Molecular Formula:
C101H155N29O39S
Molecular Weight:
2431.58
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
M9241
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
M9241
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AGANIRSEN
2
Oligonucleotide
Investigational
Unknown
Unknown
Unknown
Insulin receptor substrate 1 mRNA antisense inhibitor
AGANIRSEN
×
Maximum Phase:
2
First Approval:
None
UNII:
0N3FY8225K
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LUCANTHONE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LUCANTHONE
×
Maximum Phase:
2
First Approval:
None
UNII:
FC6D57000M
Molecule Type:
Small molecule
Molecular Formula:
C20H24N2OS
Molecular Weight:
340.49
AlogP:
4.48
PSA:
32.34
HBD:
1.0
HBA:
#RotB:
6.0
Source:
PORGAVIXIMAB
2
Antibody
Investigational
Unknown
Unknown
Hemorrhagic Fever, Ebola
Unknown
PORGAVIXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
07EY0HWO2M
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
INTRON-A
2
Protein
Investigational
Unknown
Unknown
Unknown
Unknown
INTRON-A
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ROGARATINIB
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Neoplasms; Urinary Bladder Neoplasms
Fibroblast growth factor receptor inhibitor
ROGARATINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
98BSN6N516
Molecule Type:
Small molecule
Molecular Formula:
C23H26N6O3S
Molecular Weight:
466.57
AlogP:
2.59
PSA:
107.01
HBD:
2.0
HBA:
#RotB:
6.0
Source:
RETINOIC ACID RECEPTOR .GAMMA.
2
Unknown
Investigational
Unknown
Unknown
Emphysema
Unknown
RETINOIC ACID RECEPTOR .GAMMA.
×
Maximum Phase:
2
First Approval:
None
UNII:
OSD7UB9MEE
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ANFIBATIDE
2
Protein
Investigational
Unknown
Unknown
Myocardial Infarction; Purpura, Thrombotic Thrombocytopenic
Platelet glycoprotein Ib alpha chain antagonist
ANFIBATIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
DCG29J773G
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GLYCERINATED GERMAN COCKROACH ALLERGENIC EXTRACT
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
GLYCERINATED GERMAN COCKROACH ALLERGENIC EXTRACT
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VIAGENPUMATUCEL-L
2
Cell
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung
Unknown
VIAGENPUMATUCEL-L
×
Maximum Phase:
2
First Approval:
None
UNII:
13H90KC831
Molecule Type:
Cell
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
192
193
194
195
196
197
198
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA